Enhancement of SARS-CoV-2 Infection via Crosslinking of Adjacent Spike Proteins by N-Terminal Domain-Targeting Antibodies

Viruses. 2023 Dec 13;15(12):2421. doi: 10.3390/v15122421.

Abstract

The entry of SARS-CoV-2 into host cells is mediated by the interaction between the spike receptor-binding domain (RBD) and host angiotensin-converting enzyme 2 (ACE2). Certain human antibodies, which target the spike N-terminal domain (NTD) at a distant epitope from the host cell binding surface, have been found to augment ACE2 binding and enhance SARS-CoV-2 infection. Notably, these antibodies exert their effect independently of the antibody fragment crystallizable (Fc) region, distinguishing their mode of action from previously described antibody-dependent infection-enhancing (ADE) mechanisms. Building upon previous hypotheses and experimental evidence, we propose that these NTD-targeting infection-enhancing antibodies (NIEAs) achieve their effect through the crosslinking of neighboring spike proteins. In this study, we present refined structural models of NIEA fragment antigen-binding region (Fab)-NTD complexes, supported by molecular dynamics simulations and hydrogen-deuterium exchange mass spectrometry (HDX-MS). Furthermore, we provide direct evidence confirming the crosslinking of spike NTDs by NIEAs. Collectively, our findings advance our understanding of the molecular mechanisms underlying NIEAs and their impact on SARS-CoV-2 infection.

Keywords: SARS-CoV-2; cross-linking; cryo-EM; infection enhancing antibody; molecular dynamics; spike protein.

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Protein Binding
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus

Substances

  • Angiotensin-Converting Enzyme 2
  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Antibodies, Viral

Grants and funding